Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
1.055
+0.015 (1.44%)
Nov 21, 2024, 1:57 PM EST - Market open
Ovid Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Ovid Therapeutics stock have an average target of 4.04, with a low estimate of 1.20 and a high estimate of 8.00. The average target predicts an increase of 282.94% from the current stock price of 1.06.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 30, 2024.
Analyst Ratings
The average analyst rating for OVID stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3 | Strong Buy | Reiterates | $3 | +184.36% | Sep 30, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3 | Strong Buy | Reiterates | $3 | +184.36% | Aug 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3 | Strong Buy | Reiterates | $3 | +184.36% | Jul 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3 | Strong Buy | Reiterates | $3 | +184.36% | Jul 2, 2024 |
| BTIG | BTIG | Strong Buy Maintains $11 → $5 | Strong Buy | Maintains | $11 → $5 | +373.93% | Jun 18, 2024 |
Financial Forecast
Revenue This Year
475.96K
from 391.70K
Increased by 21.51%
Revenue Next Year
35.23M
from 475.96K
Increased by 7,300.79%
EPS This Year
-0.44
from -0.74
EPS Next Year
-0.40
from -0.44
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 735,000 | 188.4M | 92.9M | ||
| Avg | 475,963 | 35.2M | 30.2M | ||
| Low | 294,000 | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 87.6% | 39,476.6% | 163.8% | ||
| Avg | 21.5% | 7,300.8% | -14.2% | ||
| Low | -24.9% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.36 | 1.47 | 0.15 | ||
| Avg | -0.44 | -0.40 | -0.70 | ||
| Low | -0.61 | -0.89 | -1.64 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.